InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...read more
InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
LITTLE ROCK, AR, USA, September 20, 2021 - InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in Meth-OD, a Phase 2 study of the first-in-class anti-methamphetamine antibody IXT-m200 in patients...read more
InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 - InterveXion Therapeutics, a private clinical-stage biopharmaceutical company...read more
Binding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of people with methamphetamine overdose and methamphetamine use disorder. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and has demonstrated positive Phase 2 clinical proof-of-concept data (STAMPOUT; NCT03336866). We are currently evaluating IXT-m200 in a Phase 2 study for methamphetamine overdose (Meth-OD), and we are planning another Phase 2 study of IXT-m200 in people with methamphetamine use disorder (OUTLAST).